UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000047431
Receipt number R000054088
Scientific Title Immune checkpoint inhibitors for ocular melanoma
Date of disclosure of the study information 2022/04/07
Last modified on 2024/04/03 14:06:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Immune checkpoint inhibitors for ocular melanoma

Acronym

Immune checkpoint inhibitors for ocular melanoma

Scientific Title

Immune checkpoint inhibitors for ocular melanoma

Scientific Title:Acronym

Immune checkpoint inhibitors for ocular melanoma

Region

Japan


Condition

Condition

Ocular melanoma

Classification by specialty

Ophthalmology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate ORR, DCR, PFS, and OS among patients with ocular melanoma who were treated with ICI.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

ORR, DCR, PFS, and OS among patients with ocular melanoma who were treated with ICI.

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with ocular melanoma who were treated with ICI

Key exclusion criteria

Patients with ocular melanoma who were treated with ICI as adjuvant/neoadjuvant therapy

Target sample size



Research contact person

Name of lead principal investigator

1st name Nobuyuki
Middle name
Last name Horita

Organization

Yokohama City University Hospital

Division name

Chemotherapy Center

Zip code

236-0004

Address

3-9, Fukuura, Kanazawa, Yokohama

TEL

045-787-2800

Email

horitano@yokohama-cu.ac.jp


Public contact

Name of contact person

1st name Nobuyuki
Middle name
Last name Horita

Organization

Yokohama City University Hospital

Division name

Chemotherapy Center

Zip code

236-0004

Address

3-9, Fukuura, Kanazawa, Yokohama

TEL

045-787-2800

Homepage URL


Email

horitano@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City University Hospital

Institute

Department

Personal name



Funding Source

Organization

Yokohama City University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yokohama City University Hospital

Address

3-9, Fukuura, Kanazawa, Yokohama

Tel

045-787-2800

Email

horitano@yokohama-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 04 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2022 Year 04 Month 07 Day

Date of IRB

2022 Year 04 Month 07 Day

Anticipated trial start date

2022 Year 04 Month 07 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Only English full article will be eligible.
Random-model meta-analysis with generic inverse variance will be conducted to pool the data.


Management information

Registered date

2022 Year 04 Month 07 Day

Last modified on

2024 Year 04 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054088


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name